Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.

Hodgkin lymphoma is a curable disease in the vast majority of cases with a cure rate approaching 85 to 95% with initial therapy. However, some patients experience relapse and in patients with relapsed/refractory disease, prognosis remains poor and active agents are needed in this setting. Bendamustine is an alkylating agent with clinical activity against various lymphomas including follicular, mantle, diffuse large B cell lymphoma, and chronic lymphocytic leukemia; however, its activity in Hodgkin lymphoma is not yet well established. We report a case of a 55-year-old man with relapsed Hodgkin lymphoma that is heavily pretreated and was successfully treated with four cycles of single agent bendamustine (90 mg/m(2)) with complete response after two cycles and without any significant toxicity. These findings suggest that bendamustine is highly active in Hodgkin lymphoma.

Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.

Both 5-FU and oxaliplatin have been used as single agents in patients with colorectal cancer and severe liver dysfunction, but the combination of these drugs has not yet been investigated. A 67-year-old man diagnosed with colorectal cancer in 2008 presented in April 2011 to Appalachian Regional Healthcare Cancer Center with obstructive jaundice and weight loss. Imaging studies were compatible with a liver mass and dilatation of the intrahepatic bile ducts. A liver biopsy confirmed metastatic colorectal cancer. Because his total bilirubin level was 23.1 mg/dL, a percutaneous catheter was placed in May 2011. His total bilirubin level decreased to 5.9 mg/dL, but then increased to 9.4 mg/dL in June 2011. He was started on a FOLFOX regimen, with a 50% dose reduction of 5-FU bolus (200 mg/m(2)) and continuous infusion (1200 mg/m(2)) over 46 hours, and a 15% dose reduction of oxaliplatin (75 mg/m(2)) every 2 weeks. He tolerated this regimen very well, with normalization of his bilirubin level, a significant decrease in his tumor markers, and a partial response seen on PET/CT scan. His only significant toxicity was a grade 2 stomatitis. He received 21 cycles of FOLFOX, and was later switched to cetuximab treatment after disease progression. These findings suggest that FOLFOX might be effective in metastatic colon cancer with severe liver dysfunction, with minimal toxicity, and deserves further investigation.